Today's Daily Dose brings you news about encouraging efficacy data about Pfizer/BioNTech's COVID-19 vaccine candidate, Calliditas' primary IgA nephropathy trial results, FDA refusing to approve Supernus' ADHD drug candidate, a possible delay in the FDA decision of Revance's DaxibotulinumtoxinA for frown lines, and Affimed's licensing agreement with Roivant Sciences.
from RTT - Biotech https://ift.tt/36oi0fx
via IFTTT
No comments:
Post a Comment